ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.002,02
-1,43%
S&P 500
5.431,60
-0,04%
Dow Jones
38.589,16
-0,15%
Euro vs US Dollar
1,07175
0,00%
Bitcoin
66.503,38
0,47%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Sunshine Biopharma Inc (SBFMW)

  7. Sunshine Biopharma Inc (SBFMW) News

SBFMW

Sunshine Biopharma (SBFMW)

Sunshine Biopharma Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:SBFMW
DatumZeitQuelleÜberschriftSymbolFirma
11/06/202422h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SBFMWSunshine Biopharma Inc
07/06/202422h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SBFMWSunshine Biopharma Inc
22/05/202422h11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SBFMWSunshine Biopharma Inc
20/05/202421h34Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SBFMWSunshine Biopharma Inc
15/05/202416h40Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:SBFMWSunshine Biopharma Inc
08/05/202422h21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SBFMWSunshine Biopharma Inc
06/05/202418h14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SBFMWSunshine Biopharma Inc
04/12/202314h30GlobeNewswire Inc.Sunshine Biopharma Moves Principal Office to New York CityNASDAQ:SBFMWSunshine Biopharma Inc
11/08/202314h30GlobeNewswire Inc.Sunshine Biopharma Reports 2023 Second Quarter Results: Revenues Up 3,600%NASDAQ:SBFMWSunshine Biopharma Inc
16/05/202315h58GlobeNewswire Inc.Sunshine Biopharma Announces Closing of $5.0 Million Private Placement Priced At-the-MarketNASDAQ:SBFMWSunshine Biopharma Inc
12/05/202314h00GlobeNewswire Inc.Sunshine Biopharma Announces Pricing of $5.0 Million Private Placement Priced At-the-MarketNASDAQ:SBFMWSunshine Biopharma Inc
11/05/202315h00GlobeNewswire Inc.Sunshine Biopharma Reports 2023 First Quarter Results: Revenues Up 2,100%NASDAQ:SBFMWSunshine Biopharma Inc
05/04/202314h00GlobeNewswire Inc.Sunshine Biopharma Reports Full Year Ended December 31, 2022 Financial Results and Provides Corporate UpdateNASDAQ:SBFMWSunshine Biopharma Inc
28/02/202313h30GlobeNewswire Inc.Sunshine Biopharma Signs Exclusive Worldwide License With University of Arizona For PLpro-Based Covid-19 TreatmentNASDAQ:SBFMWSunshine Biopharma Inc
10/02/202313h35GlobeNewswire Inc.Sunshine Biopharma Signs Research Agreement With the Jewish General Hospital to Advance the Development of Adva-27a Anticancer CompoundNASDAQ:SBFMWSunshine Biopharma Inc
19/01/202313h30GlobeNewswire Inc.Sunshine Biopharma Announces Share Repurchase ProgramNASDAQ:SBFMWSunshine Biopharma Inc
20/12/202214h00GlobeNewswire Inc.Sunshine Biopharma’s Annual Letter to ShareholdersNASDAQ:SBFMWSunshine Biopharma Inc
16/11/202214h00GlobeNewswire Inc.Sunshine Biopharma Enters Into a Collaboration Agreement with a Leading Lipid Nanoparticle Formulation Company for Its K1.1 Anticancer mRNA ProjectNASDAQ:SBFMWSunshine Biopharma Inc
20/10/202214h00GlobeNewswire Inc.Sunshine Biopharma Announces the Acquisition of Nora Pharma, Adding $10.7 Million in RevenueNASDAQ:SBFMWSunshine Biopharma Inc
04/08/202214h00GlobeNewswire Inc.Sunshine Biopharma Files Its Second Quarter Report With the SECNASDAQ:SBFMWSunshine Biopharma Inc
28/07/202214h10GlobeNewswire Inc.Sunshine Biopharma Increases Support for Anti-Coronavirus Collaborative Research With the University of ArizonaNASDAQ:SBFMWSunshine Biopharma Inc
28/04/202222h50GlobeNewswire Inc.Sunshine Biopharma, Inc. Announces Closing of $19.5 Million Private Placement Priced At-the-MarketNASDAQ:SBFMWSunshine Biopharma Inc
26/04/202206h41GlobeNewswire Inc.Sunshine Biopharma, Inc. Announces Pricing of $19.5 Million Private Placement Priced At-the-MarketNASDAQ:SBFMWSunshine Biopharma Inc
25/04/202214h00GlobeNewswire Inc.Sunshine Biopharma Files Patent Application Covering Recently Announced mRNA Molecules Found To Be Effective At Destroying Multidrug Resistant Cancer CellsNASDAQ:SBFMWSunshine Biopharma Inc
05/04/202214h00GlobeNewswire Inc.Sunshine Biopharma’s Newly Designed mRNA Molecules Prove Effective Against Multidrug Resistant Cancer CellsNASDAQ:SBFMWSunshine Biopharma Inc
14/03/202223h12GlobeNewswire Inc.Sunshine Biopharma, Inc. Announces Closing of $8.0 Million Private Placement Priced At-the-MarketNASDAQ:SBFMWSunshine Biopharma Inc
10/03/202215h17GlobeNewswire Inc.Sunshine Biopharma, Inc. Announces Pricing of $8.0 Million Private Placement Priced At-the-MarketNASDAQ:SBFMWSunshine Biopharma Inc
25/02/202216h20InvestorsHub NewsWireSUNSHINE BIOPHARMA EXPANDS ANTI-CORONAVIRUS DRUG DEVELOPMENT PROGRAM BY SIGNING A COLLABORATION AGREEMENT WITH THE UNIVERSITY OF ARIZONANASDAQ:SBFMWSunshine Biopharma Inc
25/02/202214h00GlobeNewswire Inc.Sunshine Biopharma Expands Anti-Coronavirus Drug Development Program By Signing A Collaboration Agreement With The University Of ArizonaNASDAQ:SBFMWSunshine Biopharma Inc
17/02/202216h07GlobeNewswire Inc.Sunshine Biopharma, Inc. Announces Closing of $8 Million Public Offering and Uplisting to the Nasdaq Capital MarketNASDAQ:SBFMWSunshine Biopharma Inc
 Showing the most relevant articles for your search:NASDAQ:SBFMW

Kürzlich von Ihnen besucht

BIT
S27875
Societe Generale Effekten
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten